Sarepta reports preliminary Q4 net product revenue $369.9M

Sarepta (SRPT) Therapeutics reports preliminary fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, restricted cash and investments on hand as of December 31, 2025, as part of its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. Total net product revenue of $369.6M for the fourth quarter and $1.86B for full-year 2025. Sarepta’s net product revenue does not include collaboration, contract manufacturing or royalty revenue. Fourth quarter and full-year 2025 net product revenue for ELEVIDYS totaled $110.4M and $898.7 million, respectively. Fourth quarter and full-year 2025 net product revenue for Sarepta’s PMOs totaled $259.2 million and $965.6M, respectively. As of Dec. 31, 2025, the Company had preliminary cash, cash equivalents, restricted cash and investments of approximately $953.8M. “Sarepta faced and overcame challenges in 2025, achieving meaningful pipeline progress and solid performance,” said Doug Ingram, CEO. “In the face of obstacles, we achieved $1.86B in total net product revenue, and ELEVIDYS achieved $898.7M. At $110.4M, ELEVIDYS fourth quarter revenue was impacted by the severe year-end flu season and the need in December to reschedule 6 patient infusions into 2026. At $965.6M in durable revenue, our PMO franchise continued to deliver for patients. And importantly, we generated another quarter of positive cash flow and ended the year with $953.8M in cash, cash equivalents, restricted cash and investments, giving us the financial strength to fully invest in our approved therapies and advance our next-generation siRNA pipeline. We have important initiatives in 2026 to continue the success of our approved therapies, particularly ELEVIDYS. We previously set a yearly sales floor for ELEVIDYS of $500M. We reconfirm that floor and our intentions to exceed it. However, we will stop short of providing more detailed guidance until we begin to evaluate the results of our initiatives. We enter 2026 on a strong financial footing, with significant opportunities with our four approved therapies and our exciting siRNA pipeline.”